Clinical Trial

Elements of Adaptive Immunity in Epithelial Ovarian Cancer

Completed
View on ClinicalTrials.gov →
Summary
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-07.
Trial Details
NCT Number NCT07528911
Lead Sponsor Hellenic Cooperative Oncology Group
Collaborators: Attikon Hospital
Conditions Epithelial High Grade Serous Ovarian Cancer
Enrollment 687 participants
Start Date 2023-04-01
Primary Completion 2025-04-01 (estimated)
Study Completion 2025-06-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-27